Navigation Links
The Hepatitis C Virus Drug Market Will More Than Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
Date:11/16/2010

BURLINGTON, Mass., Nov. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launch of several novel agents, the hepatitis C virus (HCV) drug market will more than triple from approximately $2 billion in 2009 to nearly $7.5 billion in 2014 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Thereafter, the market will substantially decrease to $4.6 billion in 2019 due to decreasing prevalence of the disease and the high efficacy of new treatment regimens.

The Pharmacor 2010 findings from the topic entitled Hepatitis C Virus reveal that the standard of care for the indication will change significantly with the introduction of new classes of HCV-specific antiviral agents, such as protease inhibitors and polymerase inhibitors. Compounds from these new classes will initially be added to the backbone of currently used agents, forming triple or quadruple treatment regimens that are expected to be more efficacious than the current standard of care -- peg-IFN/ribavirin.

"Although complete elimination of peg-IFNs and ribavirin agents is highly desirable owing to their side effects, this change is unlikely to occur over the next decade," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "However, decreased treatment durations resulting from the addition of new antivirals could increase the tolerability of treatment regimens. The launch of novel HCV-specific agents will increase the size of the drug-treated population, owing mainly to re-treatment of prior non-responders as well as increased referral and drug-treatment rates."

The current standard of care for HCV -- often a nearly year-long treatment -- cures only about half of patients and is associated with severe side effects. Although the incidence of HCV has declined dramatically after the introduction of prevention measures such as b
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Drug in New Hepatitis C Clinical Trial
3. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
6. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
7. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
8. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
9. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
10. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- AARP Foundation today announced it has established a ... from the severe cold weather that has gripped much ... to helping those in need; so to support these ... dollar-for-dollar contributions up to $250,000, which could mean up ... administered through AARP Foundation. (Logo: ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion ... today announced that it has received commitments from ... $15 million of the Company,s common stock in ... dedicated health care fund. The Company ... pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... -- Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer ... VPHM).   As a result of the waiver, ... Shire expects to complete the tender offer on January 24, ... satisfaction of all of the remaining conditions to the tender ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... two went without, while 87% of younger patients got it ... colon cancer patients are less likely than younger ones to ... new study reveals. , The research indicates that those with ... are both less likely to receive chemotherapy and more likely ...
... March 16 When the Friends of Mel Foundation learned in 2007 that there might be lead in the signature bracelet -- that they ... replacing the lead components with silver-plated rings. , ... , ... ...
... more appropriate follow-up and shorter time to diagnostic resolution ... a mammogram, according to a report in the March ... one of the JAMA/Archives journals. Rebecca Lobb, ... City Health, St. Michael,s Hospital, Toronto, and colleagues studied ...
... scientists and others interested in finance, entrepreneurship and the ... Society (ACS) Small & Medium Business Webinar on employee ... matter experts and global thought leaders in chemical sciences, ... to scientific and engineering professionals. Each webinar includes ...
... ... natural or man-caused disasters. , ... Spokane, WA (PRWEB) March 16, 2010 -- IT-Lifeline, the Northwest’s foremost provider ... will team up to provide a fully equipped facility designed to accommodate hundreds of ...
... Determining sensitivity can prevent bleeding, clotting problems, study shows ... genetic test that helps doctors determine the best dose ... reduce hospitalizations by one-third during the early dose-adjustment phase, ... variations in two genes that strongly influence sensitivity to ...
Cached Medicine News:Health News:Older Colon Cancer Patients Less Likely to Get Chemo 2Health News:Older Colon Cancer Patients Less Likely to Get Chemo 3Health News:Older Colon Cancer Patients Less Likely to Get Chemo 4Health News:An Update on Mel's Bracelet 2Health News:IT-Lifeline and Red Lion Hotels Offer Business Continuity Services 2Health News:DNA Test May Cut Hospitalizations Caused by Blood Thinner 2
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... TowerPack is an innovative, quick ... Diamond Tips. Use 60% less space ... less plastic. With this amazingly easy-to-use, ... box for the whole range of ...
... use: when presented in convenient, steady, ... to pick up directly from the ... 96 tips are loaded without manual ... a security sticker. Fully autoclavable, Tipacks ...
This pipette tip facilitates the loading of samples onto polyacrylamide gels for DNA sequencing. The Geloader Tip has a 15 mm capillary with a defined diameter of less than 0.3 mm. The flexibility of...
Medicine Products: